Clinically, our data indicate that GLP-1 receptor agonists may be a valuable supplementary therapy for some infertile individuals with obesity and PCOS, especially when metabolic abnormalities are implicated in reproductive failure. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.